RCUS - Arcus Biosciences, Inc.

NYSE - NYSE Delayed Price. Currency in USD
10.90
-0.33 (-2.94%)
At close: 4:02PM EDT
Stock chart is not supported by your current browser
Previous Close11.23
Open11.17
Bid10.86 x 1000
Ask10.95 x 800
Day's Range10.76 - 11.33
52 Week Range8.57 - 17.50
Volume45,400
Avg. Volume87,674
Market Cap485.427M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-1.43
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est21.40
Trade prices are not sourced from all markets
  • What Kind Of Shareholders Own Arcus Biosciences, Inc. (NYSE:RCUS)?
    Simply Wall St.12 days ago

    What Kind Of Shareholders Own Arcus Biosciences, Inc. (NYSE:RCUS)?

    If you want to know who really controls Arcus Biosciences, Inc. (NYSE:RCUS), then you'll have to look at the makeup of its share registry. Insiders often own a large chunk of younger, smaller, companies while huge companies tend to...

  • Arcus Biosciences, Inc. (RCUS) Shares March Higher, Can It Continue?
    Zacks12 days ago

    Arcus Biosciences, Inc. (RCUS) Shares March Higher, Can It Continue?

    As of late, it has definitely been a great time to be an investor in Arcus Biosciences, Inc. (RCUS).

  • Business Wire29 days ago

    Arcus Biosciences Appoints Rekha Hemrajani as Chief Operating and Financial Officer

    Arcus Biosciences, Inc. (RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies, today announced the appointment of Rekha Hemrajani as Chief Operating and Financial Officer. Ms. Hemrajani will be responsible for several key areas, including finance, investor relations, corporate communications, business and corporate development, strategic planning and human resources. “We are thrilled to welcome Rekha as a key member of our senior leadership team, as we enter an exciting period in Arcus’s development with multiple Phase 1 readouts for AB928, our dual A2a/A2b receptor antagonist, AB154, our anti-TIGIT antibody, and AB680, our small-molecule CD73 inhibitor,” said Terry Rosen, Ph.D., Chief Executive Officer of Arcus.

  • Infinity Inks Deal With Roche for Phase II Study of IPI-549
    Zackslast month

    Infinity Inks Deal With Roche for Phase II Study of IPI-549

    Shares of Infinity (INFI) rise after the company inks deal with Roche to initiate a phase II MARIO-3 study on IPI-549. Per the deal, Roche will supply Tecentriq (atezolizumab) to Infinity.

  • Business Wire2 months ago

    Arcus Biosciences Announces Fourth Quarter and Full Year 2018 Financial Results and Recent Corporate Updates

    - Ended 2018 with four molecules in clinical development, including AB928, the Company’s dual A2aR/A2bR receptor antagonist, which is being evaluated in several dose-escalation tri

  • Business Wire2 months ago

    Arcus Biosciences Announces Upcoming Presentations at the 2019 American Association for Cancer Research Annual Meeting

    Arcus Biosciences, Inc. , a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies, today announced seven presentations at the 2019 American Association for Cancer Research Annual Meeting being held March 29-April 3, 2019 in Atlanta, Georgia.

  • Business Wire2 months ago

    Arcus Biosciences Announces Participation at Upcoming Investor Conference

    Arcus Biosciences, Inc. (RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies, today announced that Terry Rosen, Ph.D., Chief Executive Officer, will participate in a fireside chat at the 8th Annual Leerink Partners Global Healthcare Conference on Wednesday, February 27, 2019 at 11:30 am ET at the Lotte New York Palace, in New York, NY. Arcus Biosciences is a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies. Arcus has several programs targeting important immuno-oncology pathways, including a dual adenosine receptor antagonist AB928, which is in a Phase 1/1b program to evaluate AB928 in combination with other agents in multiple tumor types, and an anti-PD-1 antibody AB122, which is being evaluated in a Phase 1 trial and is being tested in combination with Arcus’s other product candidates.

  • Why Arcus Biosciences, Eldorado Gold, and Esperion Therapeutics Slumped Today
    Motley Fool4 months ago

    Why Arcus Biosciences, Eldorado Gold, and Esperion Therapeutics Slumped Today

    Even in a surging market, these stocks fell. Find out why.

  • Business Wire4 months ago

    Arcus Biosciences Announces Transition of Chief Financial and Operating Officer

    Arcus Biosciences, Inc. (RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies, today announced that Jennifer Jarrett will step down as the Company’s Chief Financial and Operating Officer, effective January 11, 2019, to pursue an opportunity at a privately-held transportation and technology company. Ms. Jarrett will remain actively engaged with the Company and has been appointed to Arcus’s Board of Directors commencing January 12, 2019. Ms. Jarrett and the Company have also entered into a consulting agreement that will ensure a seamless transition.

  • American City Business Journals4 months ago

    Here are the winners and losers from Bay Area's IPO class of 2018

    Most stocks from last year's class of Bay Area IPO companies ended the year in positive territory, with 23 of them closing 2018 above their IPO offering prices. Here's a look at all of them, as Wall Street volatility threatens the planned 2019 IPOs of a number of the most closely watched startups.

  • This year's Bay Area IPO batch remains up 44% despite market turbulence
    American City Business Journals5 months ago

    This year's Bay Area IPO batch remains up 44% despite market turbulence

    Stocks from eight of the 34 companies from the region that went public this year are now below their IPO price. Six others are trading at double or more where they started.

  • GlobeNewswire5 months ago

    Consolidated Research: 2018 Summary Expectations for ProQR Therapeutics N.V, Biomerica, VEREIT, Apergy, Zendesk, and Arcus Biosciences — Fundamental Analysis, Key Performance Indications

    NEW YORK, Nov. 16, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • Business Wire5 months ago

    Arcus Biosciences Presents Initial Data from the Phase 1 Dose-Escalation Study of AB122, its anti-PD-1 antibody, at the SITC 2018 Annual Meeting

    Arcus Biosciences, Inc. (RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies, today announced preliminary data from its ongoing Phase 1 dose-escalation study of AB122. The data are being presented today during a poster presentation at the Society for Immunotherapy of Cancer (SITC) Annual Meeting in Washington, D.C. “Preclinical data previously demonstrated that AB122 has biological, pharmacokinetic and pharmacodynamic properties similar to those of the approved anti-PD-1 antibodies and the dose-escalation data presented today represent an important step in confirming these results in patients,” said Joyson Karakunnel, MD, MSc, FACP, Vice President of Clinical Development at Arcus.

  • Business Wire5 months ago

    Arcus Biosciences Announces Third Quarter 2018 Financial Results and Recent Corporate Updates

    - Three dose-escalation trials evaluating AB928, the Company’s dual adenosine receptor antagonist, in combination with other agents are now enrolling patients; Initial data from th

  • Business Wire6 months ago

    Arcus Biosciences Announces Participation at Three Investor Conferences in November

    Arcus Biosciences, Inc. , a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies, today announced that members of the managemen

  • Business Wire6 months ago

    Arcus Biosciences Appoints Kristen M. Hege, M.D., to its Board of Directors

    Arcus Biosciences, Inc. (RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies, today announced the appointment of Kristen M. Hege, M.D., to its Board of Directors. Dr. Hege brings more than 20 years of oncology clinical leadership experience to Arcus’s board. “We are thrilled to welcome Dr. Hege to our Board of Directors,” said Terry Rosen, Ph.D., Chief Executive Officer at Arcus.

  • Simply Wall St.6 months ago

    Do You Know Who Else Invests In Arcus Biosciences Inc (NYSE:RCUS)?

    If you want to know who really controls Arcus Biosciences Inc (NYSE:RCUS), then you’ll have to look at the makeup of its share registry. Institutions often own shares in more Read More...

  • Business Wire6 months ago

    Arcus Biosciences to Present Final Results from the Phase 1 Study of AB928 in Healthy Volunteers at ESMO 2018 Congress

    Arcus Biosciences, Inc. (RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies, today announced that it will present final results from the Phase 1 study of AB928, its dual adenosine receptor antagonist, in healthy volunteers during a poster display session at the European Society of Medical Oncology (ESMO) 2018 Congress, being held October 19-23, 2018, in Munich, Germany. The safety data to be presented will demonstrate that in this study, there was no evidence of the physiological effects of blocking adenosine that have been observed clinically with earlier adenosine receptor antagonists. Physiological effects associated with the earlier adenosine receptor antagonists that were initially designed for CNS indications may potentially limit their optimal dosing in the oncology setting.

  • Business Wire7 months ago

    Arcus Biosciences Announces Nine Abstracts Accepted for Presentation at the SITC 2018 Annual Meeting

    Arcus Biosciences, Inc. , a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies, today announced that nine abstracts have been accepted for poster presentation at the Society for Immunotherapy of Cancer Annual Meeting, which is being held from November 7-11, 2018 in Washington, D.C.

  • 24 Bay Area companies have gone public so far this year. Here's how they've done.
    American City Business Journals7 months ago

    24 Bay Area companies have gone public so far this year. Here's how they've done.

    The flood of local IPOs passed last year's total of 15 in July and appears well on its way to top the recent high 34 in 2014, with four more coming this week. Here's how the stocks from this year's crop of new Bay Area public companies have performed so far.

  • Business Wire7 months ago

    Arcus Biosciences Announces Participation at Leerink Partners Roundtable Series: Rare Disease & Oncology

    Arcus Biosciences, Inc. , a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies, today announced Terry Rosen, Ph.D., Chief Executive Officer, and Jennifer Jarrett, Chief Operating Officer and Chief Financial Officer, will participate in a fireside chat at the Leerink Partners Roundtable Series: Rare Disease & Oncology on Wednesday, October 3, 2018, at 10:30 ...

  • GuruFocus.com8 months ago

    Arcus Biosciences Inc (RCUS) CEO Terry J Rosen Bought $280,407 of Shares

    CEO of Arcus Biosciences Inc (NYSE:RCUS) Terry J Rosen bought 18,607 shares of RCUS on 08/28/2018 at an average price of $15.07 a share.

  • Business Wire8 months ago

    Arcus Biosciences Announces Participation at Two Investor Conferences in September

    Arcus Biosciences, Inc. , a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies, today announced the Company will be participa

  • Business Wire9 months ago

    Arcus Biosciences Announces Second Quarter 2018 Financial Results and Recent Corporate Updates

    - Initiated the Phase 1/1b program for AB928 combinations; Initial dose-escalation data for all four combinations expected in the first half of 2019 -

  • Business Wire9 months ago

    Arcus Biosciences to Participate in the 2018 Wedbush PacGrow Healthcare Conference

    Arcus Biosciences, Inc. , a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies, today announced that Terry Rosen, Ph.D., Chief Executive Officer, will participate in a fireside chat at the 2018 Wedbush PacGrow Healthcare Conference on Tuesday, August 14, 2018 at 2:30 pm ET at the Parker New York, in New York City, NY.